Back to School: How biopharma can reboot drug development. Access exclusive analysis here
OGS granted ATLN European marketing rights to its Zavesca (formerly Vevesca) miglustat
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury